| Biomarker ID | 61 |
| PMID | 15655565 |
| Year | 2005 |
| Biomarker | COX-2 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa Patients: PSA >10 ng/ml |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Selenium pathway,C-Myb transcription factor network, VEGF signaling pathway, Leishmaniasis,Prostaglandin biosynthesis and regulation |
| Experiment | PSA ≤10 ng/ml Vs PSA >10 ng/ml |
| Type of Biomarker | Prognostic |
| Cohort | 126 patients were chosen for the study and divided into 2 groups- Early Stage (clinically localized disease) (n=72) and Late Stage Metastatic AI disease (n=54) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.01 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | COX-2, bcl-2 and MVD (Microvessel Density) for neoangiogenesis were chosen for biomarker evaluation |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | PTGS2 |